Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b420b6d4298340e19b198383efd6e211 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b420b6d4298340e19b198383efd6e211 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b420b6d4298340e19b198383efd6e2112021-11-25T00:00:05ZMelanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)10.1136/jitc-2021-0029952051-1426https://doaj.org/article/b420b6d4298340e19b198383efd6e2112021-10-01T00:00:00Zhttps://jitc.bmj.com/content/9/10/e002995.fullhttps://doaj.org/toc/2051-1426Shahneen SandhuGrant A McArthurKate DrummondAlison WepplerTony PapenfussAmir IravaniBelinda LeeRichard J YoungKortnye SmithPeter Kar Han LauBreon FeranLorey SmithArian LasockiRamyar MolaniaChristopher AngelHanxian Aw YeangIsmael A VergaraDavid KokPaul Joseph NeesonKaren E SheppardBenjamin J SolomonBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Shahneen Sandhu Grant A McArthur Kate Drummond Alison Weppler Tony Papenfuss Amir Iravani Belinda Lee Richard J Young Kortnye Smith Peter Kar Han Lau Breon Feran Lorey Smith Arian Lasocki Ramyar Molania Christopher Angel Hanxian Aw Yeang Ismael A Vergara David Kok Paul Joseph Neeson Karen E Sheppard Benjamin J Solomon Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) |
| format |
article |
| author |
Shahneen Sandhu Grant A McArthur Kate Drummond Alison Weppler Tony Papenfuss Amir Iravani Belinda Lee Richard J Young Kortnye Smith Peter Kar Han Lau Breon Feran Lorey Smith Arian Lasocki Ramyar Molania Christopher Angel Hanxian Aw Yeang Ismael A Vergara David Kok Paul Joseph Neeson Karen E Sheppard Benjamin J Solomon |
| author_facet |
Shahneen Sandhu Grant A McArthur Kate Drummond Alison Weppler Tony Papenfuss Amir Iravani Belinda Lee Richard J Young Kortnye Smith Peter Kar Han Lau Breon Feran Lorey Smith Arian Lasocki Ramyar Molania Christopher Angel Hanxian Aw Yeang Ismael A Vergara David Kok Paul Joseph Neeson Karen E Sheppard Benjamin J Solomon |
| author_sort |
Shahneen Sandhu |
| title |
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) |
| title_short |
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) |
| title_full |
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) |
| title_fullStr |
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) |
| title_full_unstemmed |
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) |
| title_sort |
melanoma brain metastases that progress on braf-mek inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the innate pd-1 resistance signature (ipres) |
| publisher |
BMJ Publishing Group |
| publishDate |
2021 |
| url |
https://doaj.org/article/b420b6d4298340e19b198383efd6e211 |
| work_keys_str_mv |
AT shahneensandhu melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT grantamcarthur melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT katedrummond melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT alisonweppler melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT tonypapenfuss melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT amiriravani melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT belindalee melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT richardjyoung melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT kortnyesmith melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT peterkarhanlau melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT breonferan melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT loreysmith melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT arianlasocki melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT ramyarmolania melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT christopherangel melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT hanxianawyeang melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT ismaelavergara melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT davidkok melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT pauljosephneeson melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT karenesheppard melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres AT benjaminjsolomon melanomabrainmetastasesthatprogressonbrafmekinhibitorsdemonstrateresistancetoipilimumabnivolumabthatisassociatedwiththeinnatepd1resistancesignatureipres |
| _version_ |
1718414714592034816 |